| IKATI # | Igama Lomkhiqizo | Incazelo |
| I-CPD100230 | JBJ-04-125-02 R-isomer | |
| CPD3232 | I-NTN21277 | I-NTN21277, eyaziwa nangokuthi i-Gefitinib-based PROTAC 3 i-VHL-recruiting PROTAC eyenga ukucekelwa phansi kwe-EGFR ne-EGFR eziguquguqukayo nge-DC50 ye-11.7 nM kanye ne-22.3 nM ye-HCC827 cell (Exon 19 del) kanye ne-H3255R cell (L8). |
| Idatha ye-CPDB3615 | i-Nazartinib; I-EGF816; I-NVS-816 | I-Nazartinib, eyaziwa nangokuthi i-EGF816 kanye ne-NVS-816, iyisivimbeli esitholakala ngomlomo, esingenakuhlehliswa, sesizukulwane sesithathu, esikhethiwe se-epidermal growth factor receptor (EGFR) inhibitor, esinomsebenzi we-antineoplastic ongaba khona. |
| Idatha ye-CPDB0934 | I-EAI-045 | I-EAI045 ia i-EGFR inhbitor enamandla futhi ekhethiwe. I-EAI045 iqondise ukukhetha eziguquguqukayo ezingazweli emuthini ze-EGFR kodwa ivikela isamukeli sohlobo lwasendle. I-EAI045 ivimbela i-L858R/T790M-mutant EGFR enamandla aphansi we-nanomolar ekuhlolweni kwamakhemikhali ezinto eziphilayo. |
| Idatha ye-CPDB0101 | I-Poziotinib | Amafomula aqukethe i-poziotinib angaphansi kophenyo ezivivinyweni zokwelashwa zokwelashwa kwe-EGFR-mutant lung adenocarcinoma. |
| Idatha ye-CPDB0137 | I-Osimertinib Mesylate | I-Osimertinib, eyaziwa nangokuthi i-mereletinib kanye ne-AZD-9291, iyisivimbeli se-EGFR yesizukulwane sesithathu, ibonise isithembiso ezifundweni zangaphambi komtholampilo futhi inikeza ithemba ezigulini ezinomdlavuza wamaphaphu othuthukisiwe osekwazi ukumelana nama-EGFR inhibitors akhona. |
